Celcuity, Inc. (NASDAQ:CELC) Director Richard Nigon bought 7,500 shares of the stock in a transaction on Tuesday, November 28th. The stock was purchased at an average cost of $17.48 per share, with a total value of $131,100.00. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Richard Nigon also recently made the following trade(s):

  • On Tuesday, November 21st, Richard Nigon bought 8,500 shares of Celcuity stock. The stock was purchased at an average cost of $17.31 per share, with a total value of $147,135.00.

Shares of Celcuity, Inc. (NASDAQ:CELC) traded down $1.16 during trading hours on Wednesday, reaching $17.59. 32,000 shares of the company’s stock traded hands, compared to its average volume of 45,633. Celcuity, Inc. has a 1 year low of $11.10 and a 1 year high of $21.98.

Several hedge funds have recently modified their holdings of CELC. Gagnon Securities LLC bought a new stake in shares of Celcuity during the third quarter worth $2,749,000. Royce & Associates LP bought a new stake in shares of Celcuity during the third quarter worth $1,371,000. Finally, Essex Investment Management Co. LLC bought a new stake in shares of Celcuity during the third quarter worth $184,000. 13.26% of the stock is owned by institutional investors.

Separately, Craig Hallum started coverage on shares of Celcuity in a research note on Monday, October 16th. They issued a “buy” rating for the company.

ILLEGAL ACTIVITY NOTICE: This story was originally published by Daily Political and is the sole property of of Daily Political. If you are reading this story on another publication, it was illegally copied and reposted in violation of U.S. and international copyright & trademark law. The legal version of this story can be viewed at https://www.dailypolitical.com/2017/11/29/insider-buying-celcuity-inc-celc-director-buys-7500-shares-of-stock.html.

Celcuity Company Profile

Celcuity, Inc is a cellular analysis company. The Company is focused on discovering new cancer sub-types and commercializing diagnostic tests designed to significantly improve the clinical outcomes of cancer patients treated with targeted therapies. The Company’s proprietary CELx diagnostic platform uses a patient’s living tumor cells to identify the specific abnormal cellular process driving a patient’s cancer and the targeted therapy that best treats it.

Receive News & Ratings for Celcuity Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celcuity Inc. and related companies with MarketBeat.com's FREE daily email newsletter.